The combined oral contraceptive. Risks and adverse effects in perspective

Area of Science:

• Reproductive Health
• Pharmacology
• Public Health

Background:

• Original combined oral contraceptives (COCs) with higher estrogen doses were associated with significant risks.
• Newer generations utilize low-dose progestogens and reduced estrogen, necessitating updated risk-benefit assessments.

Purpose of the Study:

• To evaluate the risks and adverse effects of low-dose, new-generation progestogen combined oral contraceptives (COCs).
• To compare the safety profile of modern COCs with historical formulations.

Main Methods:

• Review of existing studies and clinical data on low-dose COCs.
• Analysis of effects on cardiovascular health, metabolism, and cancer risk.

Main Results:

• Cardiovascular risks, particularly myocardial infarction, are minimal in non-smoking women without other risk factors.
• Low-dose COCs show minimal impact on lipid and glucose metabolism.
• A slight increase in breast cancer risk may occur with prolonged use (4-8 years) initiated before age 25; cervical cancer risk may also increase.

Conclusions:

• The clinical benefits of modern low-dose COCs likely outweigh the risks.
• Adverse effects like nausea can be managed by adjusting COC formulation.
• Long-term cancer effects of newer COCs require further investigation.